Frank Karlsen

Professor

Fakultet for teknologi, naturvitenskap og maritime fag
Institutt for mikrosystemer
Campus Vestfold (G2-20)
Professor Dr. Philos Frank Karlsen er gift med 5 barn. Han er en personlig kristen og et aktivt medlem i en norsk kirke. Han har vært involvert i utviklingen av molekylære metoder og teknologi siden han startet med sin doktorgrad i 1991. Han forsvarte sin avhandling "Analyse av humant papillomavirus i intraepitelial neoplasi og karsinom av livmorhalsen" i 1998 ved Oslo universitetssykehus. Frank har jobbet med klinisk mikrobiologi, klinisk virologi, molekylær patologi, molekylær onkologi, miljø mikrobiologi, molekylærbiologi, genetikk, cellebiologi og bioteknologi siden 1986. Frank utviklet sin første lukkede akvakulturrelatert biofilm basert filter i 1987. Han har jobbet som Gründer og leder av avdeling for forskning i bioteknologiselskapet NorChip (nå PreTect AS) fra 1999 til 2010. Han mottok (sammen med de andre i NorChip) Innovasjon Norge gull premie Reodor prisen i 2003 fra Innovasjon Norge for sitt arbeid på mRNA metode for direkte påvisning av livmorhals pre-kreft. Siden 2000 har Frank deltatt i det internasjonale samfunnet av opinionsledere, og har diskutert og presentert på verdensbasis mange forskjellige emner som dekker området mellom virologi og internasjonal screening og vaksinering. Han ble professor II i 2006 og Høgskolen i Vestfold (Høgskolen i Sør-Øst Norge, USN), Norge etter en anbefaling fra den første internasjonale komiteen. Han ble 100% professor i 2010 etter en evaluering av den andre internasjonale komiteen. I 1996 startet han arbeidet med å utvikle mikro- og nanoteknologi og har initiert, ledet og deltatt i mer enn 14 store internasjonale prosjekter støttet av Norsk Forskningsråd, EU-kommisjonen, Statoil og Innovasjon Norge. Dette resultatet er et point-of-care teknologi, inkludert en kompleks integrert mikrofluid basert lab-on-a-chip brikke og instrument. Ett av selskapene, Oslofjord Ressurspark, har han startet sammen med lokale gründers i Vestfold Dette firma er nå klar til å produsere den første point-of-care-teknologi for direkte påvisning av flere mRNA. En mellomstor bedrift i Horten er klar til å etablere en produksjonslinje for første RNA baserte diagnostiskk system: Point-of-Care Nucleic Acid Diagnose (POCNAD) brikker og instrument på vegne av flere ulike akvakulturrelaterte selskaper og produsenter. Sammen med Tao Dong, fant Frank opp en helt nye Raffining teknologi som kan føre til en revolusjon i stort volum konsentrasjon, separasjon og sortering i nær fremtid. Senere bidrog Lars Roseng og Nhut Tran-Minh med sin studenter til å gjøre raffineringsbrikken enda bedre. Denne teknologien er akkurat nå i produksjon av et selskap i Sande. Frank har mer enn 120 internasjonale vitenskapelige artikler og har innlevert mer enn 28 internasjonale patentsøknad inkludert 9 patenter som er blitt innvilget. Det mest tungt studie utført ble gjort i DR Kongo mellom 2003 og 2005 rapportert i British Journal of Cancer i 2010, inkludert den berømte Dennis Mukwege (18 internasjonale priser knyttet til behandling av kvinner) og verden opinionsledere Marc Arbyn og Chris Meijer. Frank har vært hovedveileder for mange stipendiater og masterstudenter. Den siste studenten som forsvarte sin avhandling var Nhut Tran-Minth. Han arbeider med sin Post-doc studie akkurat nå også overvåket av Frank og et team fra CtrlAQUA. Nylig har Frank vært en av veilederne sammen med Dr Muchiri og Dr Muturi i prosjektet "The Utility of E6 / E7 transkripsjon Registreringsmetode for livmorhalskreft Screening ved Kenyatta National Hospital, Kenya" gjort av Mr. Cosmas Muyabwa i Nairobi og Norge. Frank var involvert i initiering av SFI CtrlAQUA fra 2014 og tillegg av Høgskolen i Sør-Øst Norge (USN) som partner i samme SFI. Frank, vokste opp i DR Kongo mellom 1966 og 1981. Han snakker flytende norsk, engelsk og swahili. Han har fungert som en virksomhet og misjon konsulent og rådgiver for en rekke organisasjoner og bedrifter i DR Kongo og Afrika de siste 30 årene. Han har startet organisasjonen Gowa (2008) i Bukavu (DRC) og har iverksatt en rekke kommersielle og makro-økonomiske prosjekter i DR Kongo på privaten siden 2008. Han har vært aktivt med å hjelpe ulike oppstartsselskaper på sin fritid siden 2006.

Ansvarsområder

Responsible for education of Master and PhD students

Repoonsibel for supervision of Bachelor, Master and PhD projects

Teaching in a Master and PhD level BioMEMS course

Responsible for the qtrlAQUA group within IMST/USN

Responsible for the complex liquid group witin IMST/USN and NMT

Supervise a number of projects within the industrial sector

Kompetanse

Master i Bioteknologi

Mastergrad i levende Aquakulturfilter

Doktorgrad i Molekylær Pathologi i kombinasjon med virology og molekylær biologi

Post-doc i molekylær vann diagnostikk

Arbeidet mange år med Mikro og Nanoteknologi og Lab-on-a-chip teknologi

Professor i BioMEMS og Mikrofabrikasjon

CV

Curriculum Vitae

My Wife is Gry Lippert Karlsen and I have Five Children: Markus, Tea, Patrick, Sivert and Hyacinte. Private address is: Hovkastet 2, 3490 Klokkarstua, Hurum/Asker, Norway

Academic Office Address:

University College in South-East Norway

Raveien 215

3184 Borre

Norway

Email and telephone

frank.karlsen@usn.no

       +47 31009397

       +47 40403480     

Frank Karlsen; Professor Dr Philos in Biotechnology and Nanotechnology

Technology and Maritime Faculty, Institute for Micro and Nanosystem Technology

Working with Lab-on-a-chip, Virology, Microbiology, Molecular Pathology, Molecular Biology, Molecular Oncology, MicroTAS, BioMEMS, Genetics, Point-of-Care Technology, Primary Health, Personal Health, Disposable Devices to Internet of Things, Sample preparation, Complex liquid, etc.

 EDUCATION

·         Norwegian University of Science and Technology

Master of Biotechnology

·         University in Oslo, Institute of Laboratory Medicine

PhD in molecular biology/molecular pathology

·         University in Oslo, Institute of Biology

Post-doc in environmental microbiology

 

 

WORK EXPERIENCE

  • 1989-1991: Research Fellow Dept. of Microbiology, Trondheim Regional Hospital

    Development of ELISA methods against Staphylococcus Aureus

  • 1992: EMBO Fellowship, Cambridge, Britain

    Mutational analysis of Human Chromosome 3 in paraffin embedded cervical tissue

  • 1991-1997: Engineering and Research Fellow, Dept of Pathology, The Norwegian Radium Hospital

Development of molecular pathological methods for analysis and diagnostics of cancer and pre-cancer.

  • 1996-1998: Post-Doc in the EC projects:

    Development and Validation of a Rapid, Tiered Suite of Methods for the Hygienic Quality of Water

  • 1998-1999: Product specialist in Organon Technica

    Clinical Microbiology and Molecular Biology

  • 1998-2010: CSO in NorChip AS

  • 2002-2007: Ammanuensis University College in Buskerud

  • 2007-2010: Professor II at the University College   

BioMEMS course 2008 and 2009, Accreditation 10

BioMEMS course, 14 days rapid course

Supervisor for PhD study 3D cell cultivation

Strategy Infrastructure in BioMEMS and Nanotechnology

  • 2010-: Fully Time Professor

    Group leader from IMST – CtrlAQUA SFI

 

 

PUBLICATIONS (120 publications including Per-Review Papers and Proceedings)

BOOK CHAPTERS (2)

PATENTS & PATENT APPLICATIONS (27)

RESEARCH PROJECTS/GRANTS EC and NFR (10)

 

SEMINARS OR LECTURES (In addition to some of the presentations shown above)

Many presentations, workshop and seminars (in the period between 2003- 2009) in Oslo, Trondheim, Bergen, Kristiansand, Stavanger, Los Angeles, San-Diego, San-Fransisco, Boston, Mexico-city, Manchester, London, New-Delhi, Freiburg, Riga, Stockholm, Copenhagen, Malmø,  Gotenborg, Berlin, Athen, Helsinki, Neuchatel, Paris, Mainz, Freiburg, Roma, Bern, Nice, Lyon, Monaco, Stralsund, Riga, Oslo, Dublin, Edinburgh, Washington DC, Amsterdam, Brussels, Nairobi, Dar-Es-Salaam, Kigali, Hong-Kong, Beijing, Sao Paulo, Rio, Hannover etc.

Curriculum Vitae

 

My Wife is Gry Lippert Karlsen and I have Five Children: Markus, Tea, Patrick, Sivert and Hyacinte. Private address is: Hovkastet 2, 3490 Klokkarstua, Hurum/Asker, Norway

 

 

Academic Office Address:

University College in South-East Norway

Raveien 215

3184 Borre

Norway

 

 

 

 

 

 

 

Email and telephone

 

 

frank.karlsen@usn.no

 

       +47 31009397

       +47 40403480

 

      

 

Frank Karlsen; Professor Dr Philos in Biotechnology and Nanotechnology

Technology and Maritime Faculty, Institute for Micro and Nanosystem Technology

Working with Lab-on-a-chip, Virology, Microbiology, Molecular Pathology, Molecular Biology, Molecular Oncology, MicroTAS, BioMEMS, Genetics, Point-of-Care Technology, Primary Health, Personal Health, Disposable Devices to Internet of Things, Sample preparation, Complex liquid, etc.

 EDUCATION

·         Norwegian University of Science and Technology

Master of Biotechnology

·         University in Oslo, Institute of Laboratory Medicine

PhD in molecular biology/molecular pathology

·         University in Oslo, Institute of Biology

Post-doc in environmental microbiology

WORK EXPERIENCE

  • 1989-1991: Research Fellow Dept. of Microbiology, Trondheim Regional Hospital

    Development of ELISA methods against Staphylococcus Aureus

  • 1992: EMBO Fellowship, Cambridge, Britain

    Mutational analysis of Human Chromosome 3 in paraffin embedded cervical tissue

  • 1991-1997: Engineering and Research Fellow, Dept of Pathology, The Norwegian Radium Hospital

Development of molecular pathological methods for analysis and diagnostics of cancer and pre-cancer.

  • 1996-1998: Post-Doc in the EC projects:

    Development and Validation of a Rapid, Tiered Suite of Methods for the Hygienic Quality of Water

  • 1998-1999: Product specialist in Organon Technica

    Clinical Microbiology and Molecular Biology

  • 1998-2010: CSO in NorChip AS

  • 2002-2007: Ammanuensis University College in Buskerud

  • 2007-2010: Professor II at the University College   

BioMEMS course 2008 and 2009, Accreditation 10

BioMEMS course, 14 days rapid course

Supervisor for PhD study 3D cell cultivation

Strategy Infrastructure in BioMEMS and Nanotechnology

  • 2010-: Fully Time Professor

    Group leader from IMST – CtrlAQUA SFI

PUBLICATIONS (120 publications including Per-Review Papers and Proceedings)

BOOK CHAPTERS (2)

PATENTS & PATENT APPLICATIONS (27)

RESEARCH PROJECTS/GRANTS EC and NFR (10)

SEMINARS OR LECTURES (In addition to some of the presentations shown above)

Many presentations, workshop and seminars (in the period between 2003- 2009) in Oslo, Trondheim, Bergen, Kristiansand, Stavanger, Los Angeles, San-Diego, San-Fransisco, Boston, Mexico-city, Manchester, London, New-Delhi, Freiburg, Riga, Stockholm, Copenhagen, Malmø,  Gotenborg, Berlin, Athen, Helsinki, Neuchatel, Paris, Mainz, Freiburg, Roma, Bern, Nice, Lyon, Monaco, Stralsund, Riga, Oslo, Dublin, Edinburgh, Washington DC, Amsterdam, Brussels, Nairobi, Dar-Es-Salaam, Kigali, Hong-Kong, Beijing, Sao Paulo, Rio, Hannover etc.

Publikasjoner

PUBLICATIONS (120 publications including Per-Review Papers and Proceedings)

 

1. Holm R., Karlsen F., Nesland J.M., In Situ Hybridization with non-isotopic probes using different detection systems. Modern Pathology, 5: p315, 1992.

 

2. Helland Å., Holm R., Kærn, J., Karlsen F., Trope, C., Nesland, J., Børresen A., TP53 Mutation and HPV-infection in Primery Cervical Carcinoma. J. Pathol. 171:105-114, 1993.

 

3. Karlsen F., Kalantari M., Chitemerere M., Hagmar B. Modification of human and viral DNA by formaldehyde fixation.  Lab Invest, 71:p604, 1994.

 

4. Karlsen F., Rabbitts P., Hagmar B., PCR-RFLP studies of chromosome 3p in HPV positive and negative paraffin embedded cervical cancer tissues. Int J Cancer, 58:p787, 1994.

 

5. Holm R., Tanum G., Karlsen F., Nesland J.M. Prevalence and physical state of human papillomavirus DNA in anal carcinomas.  Mod.Pathol. 7:p449, 1994.

 

6. Berner A., Karlsen F., Geitvik G.A., Foss S.D., Børresen A-L., Nesland J.M. P53 mutation analysis of paraffin embedded prostate cancer tissues. J of Pathol. 176:p299, 1994.

 

7. Karlsen F., Kristensen, G., Holm, R., Citemerere, M., Hagmar B.M. High incidence of Human Papillomavirus in 146 cervical carcinomas. A study using three different pairs of consensus primers, and detecting viral genomes with putative deletions. Euro. J. Cancer, 31A:p1511, 1994.

 

8. Karlsen F., Steen H., Nesland, J.M. SYBR Green I - a new DNA staining dye increases the detection sensitivity of viruses by PCR. J. Virol. Meth. 55:153-, 1994.

 

9.Karlsen F, Kalantari M, Jenkins A, Pettersen E, Kristensen G, Holm R, Johansson B, Hagmar B. Use of multiple PCR-primer sets for optimal Human Papillomavirus detection. J. Clin. Microbiol. 34:2095-2100, 1996.

 

10. Kalantari M, Karlsen F, Holm R, Jenkins A, Kristensen G, Hagmar B, Johansson B. Variable patterns of disruption of the E1 and E2 reading frames of HPV 16 in cervical cancer. Int. J. Gyn. Pathol, April 17 (2): 146-153, 1998.

 

11. Karlsen F,   Molden T,  Kalantari M, Hagmar B, Jenkins A, Suo Z, Sigurdardottir S,  Holm R. Human Papillomavirus 33 DNA isolated from CIN III and cervical carcinomas with deletions in the integrated but not in the episomal stage. Published as a part of the PhD thesis.

 

12.  Helland Å, Karlsen F, Due EU, Kristensen G, Holm R, Børresen AL. TP53 mutations, p53 expression, MDM2 expression and p21/WAF-1 expression in HPV negative and weak primary cervical carcinomas. Br J Cancer. 78(1):69-72. 1998.
 

13. Chitemerere M, Ikdahl Andersen T, Holm R, Karlsen F, Børresen A-L, Nesland JM. TP53 alteration in atypical ductual lesions and ductal carcinoma of the thyroid. Breast Cancer Res. and Treatment 41:103-109, 1996

 

14.  Kristensen GB, Karlsen F, Jenkins A, Kærn J, Abler VM, Trope CG.

Human papillomavirus has no prognostic significance in cervical carcinoma. Euro. J. Cancer., 32A:1349-1353, 1996.

 

15 Lie E,  Karlsen F, Holm R. Presence of human paillomavirus in squamous cell laryngeal carcinoma. A study of 39 cases using polymerase chain reation and in situ hybridization. Acta Oto Laryngol. 116:900-905. 1996.

 

16. Kareem N, Karlsen F, Holm Ruth, Hennig EM, Suo Zhenhe, Emilsen E, Hellesylt E, Nesland JM. A novel grid polymerase chain reaction (G-PCR) approach at ultrastructural level to detect target DNA in cell cultures and tissues J. Pathology., 183:486-493, 1997.

 

18. Åmellem Ø, Stokke T, Sandvik JA, (Karlsen F), Pettersen EO. The retinoblastoma protein-mediated cell-cycle arrest i S-phase under moderate hypoxia is disrupted in cells expressing HPV 18 E7 oncoprotein. Br J Cancer 77(6):862-72, 1998.

 

19. Kalantari M, Karlsen F, Hagmar B, Jonsson TS, Warleby B, Johansson B. HPV findings in relation to CIN-STAGE.. Human Pathology, 28:899-904, 1997.

 

20. Henning EM, Zhenhe S, Karlsen F, Holm R, Thoresen S, Nesland JM. HPV positive bronchopulmonary carcinomas in women with previous high-grade cervical intraepithelial neoplasia (CIN III). Acta Oncol 1999;38(5):639-47.

 

21.  Gulliksen A, Sollie L, Morland E, Skomedal H, Morland G, Hagen M, Rogne H, Fishmen BG, Klaus D, Sorensen O, Karlsen F, A micro fabricated system for real-time amplification and detection of up to 50 different cancer markers in 1.5 microliter of purified RNA, INTERNATIONAL JOURNAL OF CANCER, 205-205 Suppl. 13, 2002

 

22.  Anja Gulliksen, Lars Solli, Frank Karlsen, Henrik Rogne, Eivind Hovig, Trine Nordstrøm and Reidun Sirevåg, Real-time Nucleic Acid Sequence-Based Amplification in Nanoliter Volumes, Analytical Chemistry, 2004, 76, 9 – 14

 

23.  Gulliksen A, Sollie L, Morland E, Skomedal H, Morland G, Hagen M, Rogne H, Fishmen BG, Klaus D, Sorensen O, Karlsen F, A micro fabricated system for real-time amplification and detection of up to 50 different cancer markers in 1.5 microliter of purified RNA, INTERNATIONAL JOURNAL OF CANCER, 205-205 Suppl. 13, 2002

 

24.  ”high risk” human papillomavirus in relation to CIN grade, viral load and p16Ink4a. Int J. Oncol Sept 29, 2006

 

25.   Gulliksen A, Solli LA, Drese KS, Sørensen O, Karlsen F, Rogne H, Hovig E, Sirevag R. Parallel nanoliter detection of cancer markers using polymer microchips. Lab Chip, Apr 5, 2005.

 

26.  Keegan H, Mc Inerney J, Pilkington L, Grønn P, Silva I, Karlsen F, Bolger N, Logan C, Furuberg L, O'Leary J, Martin C. Comparison of HPV detection technologies: Hybrid capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens. J Virol Methods. 2009 Jan;155(1):61-6. Epub Nov 13. 2008.

 

27.  Kraus I, Molden T, Erno LE, Skomedal H, Karlsen F, Hagmar B. Human papillomavirus oncogeneic expression in the dysplastic portio; an investigation of biopsies from 190 cervical cones. Br. J. Cancer. 90:1407-13, 2004.

 

28.  Molden T, Kraus I, Karlsen F, Skomedal H, Nygård JF, Hagmar B. Comparision of human papillomavirus mRNA and DNA detection: A cross-sectional study of 4136 women > 30 years of age with a two year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiology, Biomarkers and Prevention.14(2):367-372, 2005

 

29.  Molden T,  Nygård JF, Kraus I, Karlsen F, Nygård M, Skare GB, Skomedal H, Thoresen, SØ, Hagmar B. Predicting CIN 2+ when detecting HPV mRNA and DNA by PreTect HPV-Proofer and consensus PCR: a 2-year follow-up of women with ASCUS or LSIL Pap smear cytology. International Journal of Cancer 114:973-976, 2005

 

30.  Molden T, Kraus I, Karlsen F, Skomedal F, Hagmar B. Human papillomavirus E6/E7 mRNA expression in women younger than 30 years of age. Gyn Oncology 2005.

 

31.  Kraus I, Molden T, Holm R, Lie A-K, Karlsen F, Kristensen GB, Skomedal H. Presence of E6 and E7 mRNA from Human Papillomavirus Types 16, 18, 31, 33 and 45 in the Majority of Cervical Carcinomas. J. Clin Microbiology. Apr 2006, p1310-1317

 

32.  Molden T, Nygård JF, Kraus I, Karlsen F, Nygård M, Skare GB, Skomedal H, Thoresen SØ,  Hagmar B. Predicting CIN2+ hen detecting HPV mRNA or DNA by PreTect HPV-Proofer or consensus PCR: A three-year follow-up of women with a normal Pap smear. In prep.

 

33.   Molden T, Kraus I, Skomedal H, Nordstrøm T, Karlsen F. PreTect TM HPV-Proofer: Real-time detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses. J of Virological Methods 142, 2007, 204-212.

 

34.  Gulliksen A, Karlsen F. Microchips for the diagnosis of cervical cancer. Methods Mol Biol. ;385:65-86. 2007.

 

35.  Mielnik MM, Johansen Ib-Rune, Tofteberg TR, Fismen BG, Erik Andreassen, Lutz Riegger, Koltay P, Zengerle R, Gulliksen A, Sollie L, Karlsen F, Gransee R, Baier T, Keegan H, Martin C, O’Leary J and Furuberg L. A microfluidic platform for fluorescence-based multi-target biochemical assays. Submitted Lab-on-a-chip. 2009.

 

36.  Baier T, Hansen-Hagge, Gransee R, Crombe A, Schmahl, S, Paulus, Drese KS, Keegan H, Martin C, O’Leary, JJ, Furuberg L, Solli L, Grønn P, Falang IM, Karlgård A, Gulliksen A, and Karlsen F. Hands-free sample preparation platform for nucleic acid analysis. Lab on a chip 9:3399-3405. 2009.

 

37.  Hovland S, Muller S, Skomedal H, Mints M, Bergstrøm J, Wallin K-L, Karlsen F, Johansson B, and Andersson S. E6/E7 mRNA expression analysis: a test for the objective assessment of cervical adenocarcinoma in clinical prognostic procedure. International Journal of Oncology, Jun; 36(6):1533-1539, 2010.

 

38.  Hovland S, Arbyn, M, Lie AK, Ryd W, Borge B, Berle E, Skomedal H, Kadima T, Batumbola L, Kyembwa ML, Bilayi E, Mukwge D, Chirimwami B, Kashongwe JP, Mvula M, Snijders PJ, Meijer CJ, Karlsen F. A comprehensive evaluation of cervical cancer detection methods in areas without cytology based screening possibilities. British Journal of Cancer Mars 16;102(6):957-65. 2010  

 

39. Tran-Minh N, Dong T, Su Q, Yang Z, Jakobsen H, Karlsen F. Design and optimization of non-clogging counter-flow microconcentrator for enriching epidemoid cervical carcinoma cells. Biomed Microdevices, Feb; 13(1):179-90. 2011

 

40 Dong T, Sue Q, Yang Z, Karlsen F, Jakobsen H, Egelenad EB, Hjelseth S. Cong Proc IEEE Eng Med Biol Soc. 6522-6, 2010

 

41. Pires, Nuno Miguel Matos; Dong, Tao; Yang, Zhaochu; Karlsen, Frank. Detection of pathogens using bio-activated nickel hexacyanoferrate film coated interdigitated microelectrodes. Proceedings of 2011 International  Conference on Electronic & Mechanical Engineering and Information Technology, Hardin, China, IEEE conference processing. S2841-2844.

 

42. Zhao., Xinan; Dong, Tao; Yang, Zhaochu, Karlsen, Frank; Egeland, Eirik Bentzen; Pires, Nuno Miguel Matos. A 48-well microfluidic platform based on immune-NASBA assay to quantify trqces of soluble biomarkers in water environment: Internation Symposium on Water Resource and Environmental Protection. IEEE Press 2011 s 1586-1589

 

43. Zhao, Xinyan; Dong, Tao; Yang, Zhaochu, Karlsen, Frank; Høivik, Nils. 2nd Generation of Immuno-NASBA LOC Devices for Monitoring BioMarkers in Aquatic Environment. 2nf International Conference on Remote Sensing, Environment and Transporation Engineering. Proceedings. IEEE Conference, 2012.

 

44. Gulliksen A, Keegan H, Martin C, O’Leary J, Solli LA, Falang IM, Grønn P, Karlgård A, Mielnik MM, Johansen IR, Tofteberg RT, Baier T, Gransee R, Drese K, Hansen-Hagge T, Riegger L, Koltay P, Zengerle R, Karlsen F, Ausen D, Furuberg L. Towards a “Sample-In, Answer-Out” Point-of-Care Platform for Nucelic Acid Actraction and Amplification: Using and HPV E6/E7 mRNA Model System. J. Oncol. 905024, 2012.

 

45. Rijkaard DC, Heideman DA, Coupe VM, Brink AA, Verheijen RH, Skomedal H, Karlsen F, Morland E, Snijders PJ, Meijer CJ. J. Clin Microbiol. May 2 2012.

 

46. Cuschieri K, Hardie A, Hovland S, Hoaas B, Karlsen F, Cubie H. Comparison of the sensitivities of three commercial assays for detection of the high risk HPV types 16, 18 and 45.J Virol Methods. 2013 Oct;193(1):147-50.

 

47. Hai Le The, Nhut Tran-Minh, Hoa Le Thanh, and Frank Karlsen. A Novel Micromixer with Multimixing Mechanisms for High Mixing Efficiency at Low Reynolds Number. MECBME Proceedings. Doha Febr 2014

 

48. Hoa Le-Thanh, Nhut Tran-Minh, Hai Le The, Frank Karlsen. A study on Mechanical Strength of Pyramid-shaped Microneedle. MECBME Proceedings, Doha, Febr 2014. 

 

49. Nhut Tran-Minh, Frank Karlsen, Tao Dong. A Simple and Low Cost Micromixer for Laminar Blood Mixing: Design, Optimization, and Analysis. ACBIT2013, Japan

 

50. Tran-Minh, Nhut; Le Thanh, Hoa; Karlsen, Frank. Analytical and numerical approaches for optimization design of MEMS based SU-8 microneedles. Biomedical informatics and Technology: First International Conference, Japan. Springer 2014. S105-114.

 

51. Tran-Minh, Nhut; Dong, Tao, Karlsen, Frank. An efficient passive planar micromixer with ellipse-like mi

cropillars for continous mixing of human blood. Computer Methods and Programs in Biomedicine; volum 117; s20-s29. 2014.

 

52. Le Thanh, Hoa, Le The, Hai; Nguyen, Vy; Tran-Minh, Nhut, Wang, Kaying; Karlsen Frank. Optimal design of polymer-based microneedles for improved collection of whole blood from human fingers. Micro & Nano Letters vol 9 (19) s 644-649, 2014

 

53. Le Thanh, Hoa; Tran-Minh, Nhut; Le The, Hai; Karlsen Frank. A novel design of hollow microneedle for blood sample collection: 9th IEEE International Conference ond Nano/Micro Engineered and Molecuarl Systems. Conference Proceedings s430-435. 2014

 

54. Le The, Hai; Le Thanh, Hoa; Dong, Tao; Ta, Bao Quec; Tran-Minh, Nhut; Karlsen, Frank. An effective micromixer with shifted trapezoidal blades using wide Reynolds number range. Chemical Engineering research & design, 2014, volume 93 HBV.

 

55. Le The, Hai; Le Than, Hoa; Tran-Minh, Nhut; Karlsen, Frank. A Novel passive micromixer with trapexoidal blades for high mixing efficiency at low Reynolds number flow. Middle East Conference on Biomedical Engineering. IEEE  conference proceedings. S25-s28. 2014

 

56. Le The, Hai; Tran-Minh, Nhut; Le Thanh, Hoa; Karlsen, Frank. A novel micromixer with multimixing mechanisms for high mixing efficiency at low Reynolds number. 9th IEEE International Conference on Nano/Micro Engineered and Molecular Systems (NEMS). IEEE conference proceedings s651-654.

 

57. van Aardt MC, Dreyer G, Pienaar HF, Karlsen F, Hovland S, Richter KL, Becker P. Unique human papillomavirus-type distribution in South African women with invasive cervical cancer and the effect of human immunodeficiency virus infection. Int J Gynecol Cancer. 2015 Jun;25(5):919-25

 

58. The, H. L. Thanh, H. L., Dong, T., Ta, B. Q., Tran-Minh, N. Karlsen, F. An effective passive micromixer with shifted trapezoidal blades using wide Reynolds number range. Chemical Engineering Research & Design, v93, 2015

 

59. The, H. L., Ta, B. Q., Thanh, H. L., Dong, T., Thoi, T. N.,  Karlsen, F. Geometric effects on mixing performance in a novel passive micromixer with trapezoidal-zigzag channels. Journal of Micromechanics and Microengineering, v25, 2015.

 

60. Le Thanh, H., Ta, B. Q., Le The, H., Nguyen, V., Wang, K. Y., Karlsen, F. Low-Cost Fabrication of Hollow Microneedle Arrays Using CNC Machining and UV Lithography. Journal of Microelectromechanical Systems, V24, 2015.

 

61. Nhut Tran-Minh, Frank Karlsen, Bendik Fyhn Terjesen, Hydrodynamic Study of a Continuous Large Volume Sorting and Concentration Technology for Particles and Cells in Micrometre Range, Proceedings of the 4th International Conference of Fluid Flow, Heat and Mass Transfer, DOI: 10.11159/ffhmt17.172, ISSN: 2369-3029, ISBN: 978-1-927877-37-1

 

62. Tran-Minh N., Karlsen F., Computational Fluid Dynamics Approach for Modeling a Non-Newtonian Blood Flow in a Split and Recombine Micromixer. 6th International Conference on the Development of Biomedical Engineering in Vietnam (BME6). IFMBE Proceedings, vol 63. Springer, Singapore, DOI: 10.1007/978-981-10-4361-1_53,  Print ISBN 978-981-10-4360-4 ,  Online ISBN 978-981-10-4361-1

 

 

BOOK CHAPTERS

 

 

1.     Skomedal H, Kraus I, Silva I, Molden T, Hovland S, Morland G, Morland E, Karlsen F. Direct Detection of Cervical Carcinogenesis through mRNA. p82-p102. Monsonego J (ed). Emerging issues on HPV Infections: From Sciences to Practice Basel, Karger, 2006.

2.     Gulliksen A, Karlsen F. Microchips for the diagnosis of cervical cancer. Methods Mol Biol. ;385:65-86. 2007

 

 

PATENTS & PATENT APPLICATIONS

(A)          "HPV" patent families

1.             Method for Detecting Human Papillomavirus mRNA (HPV Assay and Kit) - Granted

2.             Detection of Human Papillomavirus E6 mRNA (HPV E6I primers)

3.             Detection of Human Papillomavirus (Improved Detection of HPV)

4.             Universal Detection of Human Papillomavirus mRNA

5.             A Device for Carrying out Cell Lysis and Nucleic Acid Extraction

6.             Oligonucleotides for use in detection of human papillomavirus E7 mRNA

7.             Oligonucleotides for use in detection of human papillomavirus L1 mRNA

 

(B)          "AutoChip" patent families

1.             Microfabricated Reaction Chamber System (Reaction Chamber System) - Granted

2.             Fluid Manipulation in a Microfabricated Reaction Chamber System (Microfluidic Transportation)

3.             Nucleic Acid Fragmentation by Shear Force in a Microfluidic Device (Fragmentation Device)

4.             A Diagnostic System for Carrying Out a Nucleic Acid Sequence Amplification and Detection Process (Gynchip) - Granted

5.             A Device for Carrying Out Cell Lysis and Nucleic Acid Extraction (Gynchip II)

6.             Microfabricated device (microfabricated needle)

 

 

(C)          Other patent families

1.             Ligand Detection Method (IMRAMP) - Granted

2.             Detection of Inducible Genes in Microorganisms (Mycobacteria) - Granted

3.             A device for carrying out a biological assay (IMRAMP Chip)

4.             Improved cross flow and counter flow fluid processing devices (HIVE)

 

 

RESEARCH PROJECTS/GRANTS

·         OFU- BioMEMS- Mikrobiologi

·         EU- Microprotein- STREP

·         EU- Microactive -STREP

·         EU- Smarthealth - IP

·         EU- Microfluidics

·         EU- Microcomponents

·         EU- Self POCNAD

·         Forskningsraadet – Mikrosystemteknologi

·         Forskningsraadet – Human Papillomvirus

·         Forskningsraadet – POCNAD

 

PhD Candidates and PhD’s

·         PhD – Tor Molden, Virologi, Accepted Faculty of Medicine UIO 2006

·         PhD – Irene Kraus, Cell Biology, Accepted Faculty of Medicine UIO 2008

·         PhD – Anja Gulliksen, BioMEMS, Accepted Faculty of Mathematics and Natural Science UIO 2007

·         PhD – Lars Sollie, Microfluidics, Accepted Faculty of Engineering Science and Technology NTNU 2007

·         PhD - Ellen Tenstad, BioMEMS and Cell Biology. Accepted 2010

·         2011 – Xinyan Zhao, BioMEMS and Microbiology.

·         2012 – Nhut Tran-Minh, BioMEMS and Human fluidics

·         2012 – Birgitte Kasin Hønsvall, BioMEMS, diagnostics and microbiology.   

 

 

PROFESSIONAL ACTIVITIES

Frank Karlsen has been trained in advanced biotechnology, microbiology, pathology and molecular biology since 1989. He has presented different topics from all these fields in many conferences and meetings. Frank Karlsen have been studying molecular oncology, screening technology, molecular pathology, molecular biology and molecular virology since 1991.

Frank Karlsen has been studying biomedical Micro/Nano technology since 1996, and has been involved in Micro/Nano technological projects since 1999 with important institutes around in Europe (SINTEF, IMM, IMTEK, SENTEC; IMT) He has been invited speakers to a number of different conferences  for the last 18 years. He has been responsible for the development of different lab-on-a-chips in NorChip AS, at SINTEF and at The University College in Vestfold devices since 1999.  

 

Frank Karlsen has been active in preparing for the National Centre for Nano and Micro system technology since 1999. This activity has including hard work together with different political authorities, colleges, hospitals, companies and trade organizations on the west side of the Oslo fjord. Some of this strategy was including in the overview from the National Research Council Report related to National Centre for Nanotechnology. Different reports have been conducted by several different administrations and may be provided if necessary.

 

 

SEMINARS OR LECTURES (In addition to some of the presentations shown above)

Many presentations, workshop and seminars (in the period between 2003- 2009) in Oslo, Trondheim, Bergen, Kristiansand, Stavanger, Los Angeles, San-Diego, San-Fransisco, Boston, Mexico-city, Manchester, London, New-Delhi, Freiburg, Riga, Stockholm, Copenhagen, Malmø,  Gotenborg, Berlin, Athen, Helsinki, Neuchatel, Paris, Mainz, Freiburg, Roma, Bern, Nice, Lyon, Monaco, Stralsund, Riga, Oslo, Dublin, Edinburgh, Washington DC, Amsterdam, Brussels, Nairobi, Dar-Es-Salaam, Kigali, Hong-Kong, Beijing, Sao Paulo, Rio, Hannover etc.

 

ABSTRACTS, POSTERS and ORAL (FRANK KARLSEN):

 

1.     Halvorsen H., Karlsen F., Mæland J., "Carriage of membran proteins in Gardnerella vaginalis." Fifth Euro. Cong. Clin. Microb. Inf., Sep. 1991.

 

2.     Helland, Å., Holm, R., Kærn, J., Karlsen, F., Trope, J., Nesland, J., Børresen A.L., "TP53 Mutation and HPV-infection in Primarly Cervical Carcinoma." Third Euro. Work. Cyto. Mol. Gen. Hum. Sol. Tumors. Apr. 26, 1992.

 

3.     Karlsen, F. Kalantari, M., Chitemerere, M., Hagmar, B.M. Reaction of formaldehyde with human DNA and HPV. 12th International papillomavirus conferance. Baltimore, USA, Sept 26, 1993.

 

4.     Johnsen, H., Geitvik, G., Qvist, H., Karlsen, F., Børresen, A.L. SYBR green I - a new DNA staining dye used in constant denaturating gel electrophoresis (CDGE) and perpendicular denaturating gradient gel electrophoresis (DGGE). 21st world congress of medical technology. Hong Kong. 1994.

 

5.     Karlsen F, Kristensen G and Hagmar B. PCR-Probe analysis of 146 cervical cancer biopsies. 13th International papillomavirus conferance. Amsterdam, Netherland, Oct 8, 1994.

 

6.     Due, EU. Børresen A-L, Helland Å, Karlsen F, Holm R. Mutations analysis of the p53 gene in 24 cervical carcinomas negative or weakly positive for Human Papillomavirus (HPV). Jan , 1996.

 

7.     Kalantari M, Hagmar B, Karlsen F, Holm R, Jenkins A, Kristensen G and Johansson B. Variable patterns of disruption of the E1 and E2 reading frames of HPV 16 in cervical cancer. 15th international papillomavirus workshop, Baltimore, Australia, 1 dec. 1996.

 

8.     Karlsen F, Holm R, Hagmar B, Kalantari M, Sigurdardottir S, Kristensen G, Suo Z, Sundsfjord A, Norrild B and Jenkins A. Deletion/integration pattern of the human papillomavirus 33 genome in cervical intraepithelial neoplasia III and cervical carcinoma.15th international papillomavirus workshop, Baltimore, Australia, 1 dec. 1996.

 

9.     Hagmar B, Karlsen F, Kalantari M, Sigurjonsson T, Warlby B and Johansson B. HPV findings in relation to CIN stage. A stockholm women using PCR for detection and typing of HPV. 15th international papillomavirus workshop, Baltimore, Australia, 1 dec. 1996.

 

10.  Molden T, Kraus I, Nordstrøm T, Skomedal H, Karlsen F, Hagmar B. Evaluation of real-time multiplex NASBA as a method for detection of oncogenic E6/E7 mRNA from human papillomavirus (HPV) 18th UICC ICC USA, 2002.

 

11.  Molden T, Kraus I, Karlsen F, Skomedal H, Morland E, Hagmar B. Identification of mRNA from oncogenic HPV types in 4177 cervical smears using PreTect HPV-Proofer. International papillomavirus Conference in Paris, 2002

 

12.  Karlsen F. (Oral). PreTect HPV-Proofer and RNOMICS in Papillomavirus research, diagnostics, screening and treatment. International papillomavirus Conference in Paris, 2002

 

13.  Anja Gulliksen, Lars Solli, Frank Karlsen, Reidun Sirevåg and Henrik Rogne,

Detection of multiple real-time NASBA in nanoliter volume, Micro Total Analysis systems 2002, 3 – 7 November, Nara, Japan, Volume 1, 184 – 186

 

14.  Anja Gulliksen, Lars Solli, Klaus Stefan Drese, Olaf Sørensen, Frank Karlsen, Henrik Rogne, Real-time detection of nucleic acid sequence-based amplification (NASBA) in nanoliter volumes, smallTalk 2003, 13 – 16 July, San Jose, USA

 

15.  Karlsen F. The potential of RNA as a target for molecular diagnostics in cervical carcinoma screening. Oral presentation 21th international papillomavirus conferanse in Mexico,  2004.

 

16.  Bjerre P, Hagmar B, Dillner L, Edvardsson H, Mellinger I, Karlsson E, Karlsen F, Skomedal H and Andersson-Ellstrøm A. HPV detection as follow-up of low-grade lesions in the Swedish gynaecological screening program. Comparison between Hybrid Capture II and the RNA-based PreTect HPV-Proofer Assay. Poster 21th international papillomavirus conferanse in Mexico, 2004.

 

17.  Molden T, Kraus I, Karlsen F, Skomedal H, Nygård JF, Hagmar B. Sensitivity, specificity and predictive value of NASBA and PCR with histologically confirmed CIN2+ as endpoint. International papillomavirus conference in Mexico, 2004

 

18.  Molden T, Kraus I, Karlsen F, Skomedal H, Nygård JF, Hagmar B. High-risk HPV infections without oncogene expression are common in women younger than 30 years of age. International papillomavirus conference in Mexico, 2004

 

19.  Molden T, Kraus I, Karlsen F, Skomedal H, Nygård JF, Hagmar B. E6 and E7 mRNA expression from carcinogenic Human papillomavirus (HPV) in 4136 cervical samples collected from an outpatient population. International papillomavirus conference in Mexico, 2004

19.

 

20.  Nygård M, Karlsen F, Skomedal H, Nygård JF, Hagmar B. An evaluation of oncogene expression from HPV 16, 18, 31, 33 and 45 in samples that progress or regress from histological defined disease. International papillomavirus conference in Mexico, 2004

 

21.  Karlsen F, Molden T, Kraus I, Lie K, Hagmar B, Cuschieri K, Cubie H, Haima P, and Skomdal H. (Oral) The role of RNA as target for molecular diagnostics in cervical cancer screening.  International papillomavirus conference in Mexico, 2004.

 

22.  Molden T, Kraus I, Holm R, Karlsen F, Lie Kathrine, Kristensen GB, Hagmar B, Skomedal H. Presence of different HPV 16 transcripts in normal cells compared to CIN 2, CIN 2 and SCC biopsies. 22th IPC, Vancouver, 2005.

 

23.  Karlsen F and Skomedal H. Persistent transforming HPV infection may correlate with persistent histologically defined CIN II+. 22th IPC, Vancouver 2005.

 

24.  Grønn P, Karlsen F, Falang IM, Skomedal H. High quality mRNA can be extracted from routinely collected cervical samples by several commercially available methods and detected by PreTect HPV-Proofer. 22th IPC, Vancouver, 2005.

 

25.  Molden T, Nordstrøm, Kristiansen L, Kraus I, Karlsen F, Skomedal H. Analytical performance of the PreTect HPV-Proofer assay for detection of E6/E7 mRNA expression and typing of 5 high-risk HPVs 22th IPC, Vancouver, 2005.

 

26.  Hovland S, Lie AK, Risberg B, Ryd W, Borge B, Berle E, Skomedal H, Kadima T, Betubola L, Kyembwa ML, Bilayi E, Mukwege D, Chirimwami B, Kashongwe JP, Mvula M, Falang BM and Karlsen F. Calculation from a high risk population study. 22th IPC, Vancouver 2005.

 

27.  Karlsen F, Morland G, Skomedal H. Difference in coverage rate between DNA- and mRNA based methods for HPV positive invasive cervical carcinoma samples – A summary of studies. 22th IPC, Vancouver, 2005.

 

28.  Karlsen F, (Oral) Presentation of advanced molecular diagnostics of pre-cancer disease based on oncogene mRNA. 22th IPV, Vancouver 2005.

 

29.  Rogers R, Skomedal H, Karlsen F, DNA and mRNA based methods for detection of HPV 16, 18, 31, 33 and 45 in invasive cervical carcinoma samples – why is there a difference in coverage rate? ASCCP, USA 2006.

 

30.  Hovland S, Arbyn M, et al.,  Karlsen F. Accuracy of multiple cytological and HPV nucleic acid methods to detect CIN2+ in a highly exposed area. Eurogin, Nice, France 2006. 

 

31.  Ivan Silva, Petter Grønn, Frank Karlsen, Inger-Marie Falang and Hanne Skomedal. Quality of mRNA extracted from routinely collected cervical samples using commercial kits and its detection via PreTect HPV-Proofer. Eurogin, Nice, France 2006

 

32.  Steinberg W, Tiews S, Hanrath C, Silva I, Grønn P, Karlsen F. Evaluation of HPV testing by PreTect HPV-Proofer vs Hybrid Capture- 2-test used in cervical cancer screening, Eurogin, Nice, France 2006.

 

33.  Silva I, Skomedal H, Karlsen F, Which are the most reliable biomarkers for cervical cancer screening. XVIII FIGO,  World Congress of Gynecology and Obstetrics,  Las Vegas, USA 2006.

 

34.  Karlsen F, Silva I, Skomedal H, Monitoring oncogene expression in women with ASCUS/LSIL diagnosis. XVIII FIGO,  World Congress of Gynecology and Obstetrics,  Las Vegas, USA 2006.

 

 

35.  Karlsen F, Silva I, Skomedal H, The potential role of persistent transforming HPV infection of the cervix. XVIII FIGO,  World Congress of Gynecology and Obstetrics,  Las Vegas, USA 2006.

 

36.  Karlsen F, Silva I, Skomedal H, The combination of VLP vaccine and mRNA diagnostics of persistent transforming infection may reduce the incidence of cervical cancer worldwide by more than 95%. XVIII FIGO,  World Congress of Gynecology and Obstetrics,  Las Vegas, USA 2006.

 

37.  Karlsen F, Levett L, Liddle S, Skomedal H and Morland E. Routine HPV diangostics in clinical practice using and mRNA assay. 24th IPC, Beijing, China. 2007.

 

 

38.  Hovland S, Michael M, Skomdeal H, Karlsen F and Andersson S. HPV mRNA detection in cervical adenocarinomas. 24th IPC, Beijing, China. 2007

 

39.  Kraus I, Hovland S, Andersson S, Holm R, Karlsen F, Skomedal H. Performance of the HPV mRNA E6/E7 type specific detection assay PreTect HPV-Proofer in suboptimal sample material. 24th IPC, Beijing, China. 2007.

 

40.  Karlsen F, Skomdal H. PreTect HPV-Proofer may reduce ”hoise” compared with other screening methods used after prophylactic vaccination. 24th IPC, Beijing, China. 2007.

 

41.  Karlsen F. Classification of HPV may have been based on Biopsies from areas of Cervical Cancer that may not represent the invasive area of the tumor. 24th IPC, Beijing, China. 2007

 

42.  Morland E, Skomedal H, Kraus I, Karlsen F. Statistical assessment of data generated by diagnostic methods for detection of a rare disease. Eurogin, Monte-Carlo, Monaco, 2007

 

43.  Grønn P, Silva I, Rogers R, Falang I, Øye M, Karlsen F, and Skomedal H. Effect of different transport media on the amplification of HPV E6/E7 mRNA using the PreTect HPV-Proofer diagnostic test. Eurogin, Monte-Carlo, Monaco, 2007.

 

44.  Keegan H, McInerney J, Pilkington L, Grønn P, Silva I, Karlsen F, Bolger N, O’Leary JJ, Marin CC. (Oral) Comparison of HPV detection technologies; Hybrid Captrure II, PreTect HPV-Proofer and real-time PCR for detection of HPV in cervical cytology speciments. Eurogin, Monte-Carlo, Monaco, 2007

 

45.  Karlsen F, Skomedal H. (Oral) Potential benefit of using the PreTect HPV-Proofer assay for follow-up of the prophylactiv vaccine against cervical cancer. Eurogin, Monte-Carlo, Monaco, 2007

 

46.  Grønn P,  Falang I, Skomedal H, Karlsen F and Silva I. (Oral) Use of the SurePathTM transport media and its effect on mRNA amplification by the NASBA based PreTect HPV-Proofer diagnostic assay. Eurogin, Monte-Carlo, Monaco, 2007.

 

47.  Hovland S, Muller S, Skomedal H, Karlsen F, Andersson C. (Oral) HPV mRNA detection in different stages of cervical adenocarcinomas. Eurogin, Monte-Carlo, Monaco, 2007.

 

 

48.  Wilander E, Karlsen F (Oral). Classification of HPV may have been based on biopsies from areas of cervical cancer sample that may not represent the invasive area of the tumour. Eurogin, Monte-Carlo, Monaco, 2007.

 

49.  Karlsen F, Levett L, Liddle S, Skomdal H and Morland E. Routine HPV diangostics in clinical practice using an mRNA assay. Eurogin, Monte-Carlo, Monaco, 2007

 

50.  Solli L, Gulliksen, A, Baier T, Gransee R, Hansen-Hagge Y, Mielnik M, Johansen I-R, Furuberg L., Rigger L, Koltay P, Martin C, Keegan H, O’Leary J, Karlsen F. Development of an automatic chip based detection of mRNA. D2D Diagnostics, San Diego, USA, 2008

50.

51.  Karlsen F (Oral), Point-of-Care Nucleic Acid Diagnsotics. D2D Diangostics, San Diego, USA, 2008

 

52.  Karlsen F (Oral), Preventing Cervical Cancer By Direct Pre-Cancer Detection. Viareggio, IX International Workshop on Lower Genital Tract Pathology. 2008

 

53.  Karlsen F (Oral)., HPV E6/E7 mRNA detection in cervical cancer screening. SS18, Nice, France, Eurogin 2008.

 

54.  Karlsen F (Oral)., Prevention Cervical Cancer By Direct Pre-Cancer Detection, HPV in Pathology Congress, Prague 2008.

 

55.  Rogers R, Hovland S, Grudetjern H, Karlgård A, Øye M, Skomdal H, Kraus I, Karlsen F,  Dreyer G., Heterogenicity in cervical cancer tumors in terms of HPV types and E6/E7 expression. 25th IPC, Malmø,  Sweden. 2009.

 

56.  Rogers R, Grundetjern H, Karlgård A, Øye M, Skomedal H, Kraus I, Karlsen F,  Dreyer G. Tampon- A suitable self sampling device for detection of HPV E6/E7 mRNA from cervical cells. 25th IPC, Malmø,  Sweden. 2009.

 

57.  Rogers R, Hovland S, Grudetjern H, Karlgård A, Øye M, Skomdal H, Kraus I, Karlsen F,  Dreyer G. HPV genotype distribution in cervical cancer in south Africa and correlation between HPV DNA testing and E6/E7 mRNA testing. 25th IPC, Malmø,  Sweden. 2009.

 

58.  Karlsen F, (Oral) HPV E6/E7 mRNA detection in cervical cancer screening. Track 3-6. BITs Life Science Molecular Diagnostics Expo. Beijing, China, 2009.

 

59.  Karlsen F, (Oral) Screening of Pre-Cancer at the Doctors Office New Possibilites with Point-of-Care Nucleic Acid Diagnostic Technology. Tack 5-3. BITs Life Science Molecular Diagnostics Expo. Beijing, China, 2009. 

 

60.  Karlsen F., (Oral) Preventing Cervical Cancer By Direct Pre-Cancer Detection. HPV E6/E7 mRNA detection in cervical cancer screening. Gynecologcal Symposium. By Sul America, Sao Paulo, Brazil, 2009.

 

61.  Karlsen F., (Oral). Business case POCNAD. pHealth 2009.

 

62.  Karlsen F., (Oral). Screening Technology for Diagnosis of Pre-cancer at the Doctors Office. Micro Total Analysis Systems – Prospects, Applications and Commercialisation. Workship, Biotechnica. 2009.

 

63.  Karlsen F, Birgitte Hønsvall, Nhut Tran-Minh, Hoa Le-Thanh, Hai Le The, Vu Nguyen, Eirik Egeland and Anja Gulliksen. The complete molecular real life monitoring system for point-of-care nucleic acid diagnosis of blood and cancer disease. Oral Presentation MECBME Proceedings, Doha, Febr 2014

 

64.  Hønsvall BH, Ezkerra A, Frank Karlsen. DETECTION OF OIL-UTILIZING MICROORGANISMS BY NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION IN A TOTAL ANALYSIS

LAB-ON-A-CHIP DEVICE. MicroTAS 2013, Freiburg Germany.